InterHealth's OptiBerry[TM] shown to inhibit angiogenesis.
Recent studies published in peer reviewed journals have shown that
OptiBerry[TM], a patent-pending, standardized multiple berry extract
developed by InterHealth Nutraceuticals, possesses potent
anti-angiogenic properties, which inhibit the growth of unwanted blood
vessels involved in the formation of tumors and varicose veins.
Researchers at The Ohio State University Medical Center, Columbus, OH,
University of Kupio, Kupio, Finland and Creighton University Medical
Center, Omaha, NE, have shown that OptiBerry significantly inhibits
angiogenesis both in vitro and in vivo, thus offering potential benefit
in the treatment of related disorders such as cancer and inflammation.
The studies were published in Free Radical Research and the Federation
of European Biochemical Societies (FEBS) Letters. OptiBerry contains
numerous berry extracts, including wild blueberry, bilberry, cranberry,
elderberry, raspberry and strawberry.
For further information: 707-751-2801.